Enthera Pharmaceuticals

Italian biotechnology company developing first-in-class biologics targeting the IGFBP3/TMEM219 pathway to transform the treatment of autoimmune conditions including Type 1 diabetes.

Location
Milan, Italy
Founded
2016
Investors
1
Categories
biotech, autoimmune, biologics, therapeutics, clinical-stage

Investors

NameLocationTypeStagesPortfolio
Sofinnova PartnersParis, Francebiotech-focused
seedseries-a+3
23